Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.72 USD
Change Today +0.02 / 1.18%
Volume 428.6K
NAVB On Other Exchanges
Symbol
Exchange
NAVB is not on other exchanges.
As of 8:04 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

navidea biopharmaceuticals i (NAVB) Snapshot

Open
$1.68
Previous Close
$1.70
Day High
$1.73
Day Low
$1.65
52 Week High
12/24/14 - $2.02
52 Week Low
11/12/14 - $0.97
Market Cap
259.3M
Average Volume 10 Days
554.6K
EPS TTM
$-0.19
Shares Outstanding
150.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NAVIDEA BIOPHARMACEUTICALS I (NAVB)

navidea biopharmaceuticals i (NAVB) Related Businessweek News

View More BusinessWeek News

navidea biopharmaceuticals i (NAVB) Details

Navidea Biopharmaceuticals, Inc., a precision medicine company, focuses on the development and commercialization of precision diagnostics, therapeutics, and radiopharmaceutical agents. The company offers Lymphoseek Injection, a receptor-targeted small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients; and Manocept platform to target the CD206 mannose receptor expressed on macrophages. Its development programs include NAV4694, an Fluorine-18 radiolabeled positron emission tomography imaging agent, which is used as an aid in the diagnosis of patients with signs or symptoms of Alzheimer’s disease and mild cognitive impairment; and NAV5001, an Iodine-123 radiolabeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson’s disease and other movement disorders with potential use as a diagnostic aid in dementia. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California, AstraZeneca AB, and Alseres Pharmaceuticals, Inc. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

46 Employees
Last Reported Date: 03/16/15
Founded in 1983

navidea biopharmaceuticals i (NAVB) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $82.5K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $260.0K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $279.1K
Compensation as of Fiscal Year 2014.

navidea biopharmaceuticals i (NAVB) Key Developments

Navidea Biopharmaceuticals Announces Earnings Results for the Second Quarter of 2015

Navidea Biopharmaceuticals (NAVB)announced earnings results for the second quarter of 2015. For the quarter, sales were $2.9 million. Net loss was $0.06 per share.

Navidea Biopharmaceuticals, Inc to Report Q2, 2015 Results on Jul 30, 2015

Navidea Biopharmaceuticals, Inc announced that they will report Q2, 2015 results at 8:30 AM, US Eastern Standard Time on Jul 30, 2015

Navidea Biopharmaceuticals, Inc, Q2 2015 Earnings Call, Jul 30, 2015

Navidea Biopharmaceuticals, Inc, Q2 2015 Earnings Call, Jul 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NAVB:US $1.72 USD +0.02

NAVB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CTI BioPharma Corp $1.85 USD +0.005
Curis Inc $3.14 USD -0.06
Exact Sciences Corp $24.07 USD -0.15
View Industry Companies
 

Industry Analysis

NAVB

Industry Average

Valuation NAVB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NAVIDEA BIOPHARMACEUTICALS I, please visit www.navidea.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.